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The Alzheimer BACE1 enzyme cleaves numerous substrates,
with largely unknown physiological consequences. We have
previously identified the contribution of elevated BACE1 activ-
ity to voltage-gated sodium channel Nav1.1 density and neuro-
nal function.Here,we analyzedphysiological changes in sodium
channel metabolism in BACE1-null mice. Mechanistically, we
first confirmed that endogenous BACE1 requires its substrate,
the -subunit Nav2, to regulate levels of the pore-forming
-subunit Nav1.1 in cultured primary neurons. Next, we ana-
lyzed sodium channel -subunit levels in brains of BACE1-null
mice at 1 and3monthsof age.At both ages,we found thatNav1.1
protein levelswere significantly decreased inBACE1-null versus
wild-type mouse brains, remaining unchanged in BACE1-
heterozygous mouse brains. Interestingly, levels of Nav1.2 and
Nav1.6 -subunits also decreased in 1-month-old BACE1-null
mice. In the hippocampus of BACE1-null mice, we found a
robust 57% decrease of Nav1.1 levels. Next, we performed sur-
face biotinylation studies in acutely dissociated hippocampal
slices from BACE1-null mice. Hippocampal surface Nav1.1 lev-
els were significantly decreased, but Nav1.2 surface levels were
increased in BACE1-null mice perhaps as a compensatory
mechanism for reduced surface Nav1.1. We also found that
Nav2 processing and Nav1.1 mRNA levels were significantly
decreased in brains of BACE1-null mice. This suggests a mech-
anism consistent with BACE1 activity regulating mRNA levels
of the -subunit Nav1.1 via cleavage of cell-surface Nav2.
Together, our data show that endogenous BACE1 activity regu-
lates total and surface levels of voltage-gated sodiumchannels in
mouse brains. Both decreased Nav1.1 and elevated surface
Nav1.2 may result in a seizure phenotype. Our data caution that
therapeutic BACE1 activity inhibition in Alzheimer disease
patients may affect Nav1 metabolism and alter neuronal mem-
brane excitability in Alzheimer disease patients.
Alzheimer disease (AD)3 is a devastating neurodegenerative
disorder characterized by progressive memory loss. In the late
stages of the disease, neuropsychiatric symptoms include
depression, aggressiveness, agitation, and generalized anxiety
(1). Pathological hallmarks of AD patient brains consist of
extracellular amyloid deposits (senile plaques), neurofibrillary
tangles, and loss of neurons and synapses in the hippocampus
and the cerebral cortex (2, 3). The main component of amyloid
deposits is a short amyloid  (A) peptide most commonly of
40–42 amino acids, which derives from the amyloid precursor
protein (APP). To generate A, APP is first cleaved by -site
APP-cleaving enzyme 1 (BACE1) and subsequently by -secre-
tase. Because of their central role in A generation, it is not
surprising that the two secretases are among the prime drug
targets for AD treatment (4, 5).
BACE1 is a transmembrane aspartic protease that is ubiqui-
tously expressed with the highest levels in the brain (6, 7).
BACE1 levels and activity are increased in AD patient brains
(8–10). The reason why BACE1 is elevated in AD brains is
unknown, although it has been shown that depletion of the
adaptor protein GGA3 and phosphorylation of the translation
initiation factor eIF2 increase BACE1 levels (11, 12). Cellular
and oxidative stresses as well as energy starvation have an effect
on the enzyme function (11, 13, 14). Currently, only a few pro-
teins are known as physiological substrates of BACE1 (15–19).
To understand the physiological function of BACE1, it is essen-
tial to characterize BACE1-mediated cleavage of its neuronal
substrates.
Voltage-gated sodium channels (Nav1s) consist of one pore-
forming-subunit, associatedwith one or two-accessory sub-
units (20). Currently, 10 - and 4 -subunits have been
reported (21). The -subunits are type I single-transmembrane
proteins that regulate the localization, trafficking, and inactiva-
tion of the -subunits by direct interaction (20, 22–24). Of the
four -subunits, the 2-subunit (Nav2) appears to have a
major role in the regulation of the total and cell surface density
of sodium channels in neurons (25–27). Nav2-null mice show
altered response to pain and a reduced threshold for seizures
because of defects in electrical excitability in neurons (26, 27).
BACE1-null mice have revealed abnormalities in behavior,
cognitive, and emotional functions (28–31). An imbalance in
sodium channel function may contribute to some of these phe-
notypes. Indeed, the auxiliary 2-subunit of voltage-gated
sodium channels undergoes sequential processing by BACE1
and -secretase similar to APP (18, 19).We found that BACE1-
mediated cleavage of Nav2 alters neuronal activity (32). More-
over, elevated levels of the pore-forming -subunit Nav1.1 are
observed in AD brains with elevated BACE1 expression and
also in mice overexpressing human BACE1 (32). The 2-intra-
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cellular domain (2-ICD), derived from BACE1 and -secre-
tase-mediated cleavage of 2, regulates Nav1.1 expression.
However, Nav1.1 trafficking to the cell membrane is impaired
resulting in reduced Nav1.1 surface levels, which leads to
reduced sodium current densities (32).
Here, we asked whether endogenous BACE1 activity regu-
lates Nav1 metabolism in neuronal cells under physiological
conditions. First, we found that Nav2 is essential for BACE1
activity-dependent regulation of Nav1.1 mRNA and protein
levels in cultured embryonic neurons. Next, we also found that
endogenous BACE1 activity regulates total and surface levels of
Nav1.1 especially in adult hippocampus. Interestingly, Nav1.2
appears to compensate for decreased surface levels of Nav1.1.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—N-[N-3,5-Difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester and BACE inhibitor IV
were purchased from Calbiochem. BACE1 monoclonal anti-
body (3D5) was a kind gift fromDr. Robert Vassar (Northwest-
ernUniversity), and anti-Nav2 directed against theC terminus
of endogenous Nav2 was from Dr. Nobuyuki Nukina (RIKEN
Brain Science Institute). The following antibodies were pur-
chased for this study: anti-GAPDH (Chemicon); anti-Nav1.1
antibody (University of California, Davis/National Institutes of
Health NeuroMab Facility); anti-Nav1.2, anti-Nav1.3, and anti-
Nav1.6 (Alomone Labs); anti-Nav1s (Sigma); anti-N-cadherin
(BD Transduction Laboratories); and anti-synaptophysin
(StressGen).
Primary Neuronal Cultures—Mouse primary hippocampal/
cortical neuronal cultures were prepared and maintained in
Neurobasal media (Invitrogen) supplemented with B27 and 0.5
mM L-glutamine as described previously (18). The neuronal cul-
tures were maintained at 37 °C in a humidified 5% CO2 atmo-
sphere for 14 days. For rat primary neuronal culture, cryopre-
served rat hippocampal/cortical regions were purchased from
BrainBits (Springfield, IL), dissociated, and plated on poly-D-
lysine/laminin-coated plates. The neuronal cultures were
maintained for 14–17 days in Neurobasal media (Invitrogen)
supplemented with B27 and 0.5 mM L-glutamine.
Breeding—All animal procedures were approved by the Sub-
committee on Research Animal Care on the Use and Care of
Animals, Massachusetts General Hospital. BACE1-null and
wild-type control mice (C57BL/6J background) were pur-
chased from The Jackson Laboratory (Bar Harbor, ME).
BACE1-heterozygous knock-outmicewere generated by cross-
ing BACE1-null and wild-type control mice. Genotypes were
determined by genomic PCR using the Allele-in-One mouse
tail direct PCR system (Allele Biotechnology, San Diego)
using the following primers: 5-AGGCAGCTTTGTGGAG-
ATGGTG-3, 5-CGGGAAATGGAAAGGCTACTCC-3,
and 5-TGGATGTGGAATGTGTGCGAG-3. Nav2-null
and control mice were kindly provided by Dr. Lori L. Isom
(University of Michigan). Generation and genotyping of
Nav2-null mice were described previously (26).
Preparation of Mouse Brain Lysates—One- to 3-month-old
mice were sacrificed, and brains were immediately removed
and stored at 80 °C until use. To prepare total brain lysates,
the frozen brainswere powdered under liquid nitrogenwith the
use ofmortar and pestle. The aliquots were stored at80 °C for
individual experiments. For total brain extraction, 50–100 g
of brain powder was extracted in 5 volumes of SDS extraction
buffer (10mMTris-HCl (pH 6.8), 2% SDS, 1mMEDTA, 150mM
NaCl, a protease inhibitor mixture (Roche Applied Science), 2
mM1,10-phenanthroline, 2MMG132, and 1mMPMSF). After
incubation on ice for 10min, samples were sonicated at 4 °C for
5 min, passed through 0.22-m pore-sized filter in spin-x cen-
trifuge tubes (Costar, Corning, NY), and centrifuged for 45min
at 14,000 rpm. To prepare crude brainmembrane fractions, the
brain powderwas resuspended inTBS extraction buffer (10mM
Tris-HCl (pH6.8), 1mMEDTA, 150mMNaCl, a protease inhib-
itormixture (RocheApplied Science), 2mMPNT, 2MMG132,
and 1 mM PMSF) and passed through 22-gauge needle three
times. After brief centrifugation (500 g, 5 min), the superna-
tant was then centrifuged again at 10,000 g for 1 h. Themem-
brane pellet was then resuspended in TBS extraction buffer,
and the protein level was determined by BCA assay. For SDS-
PAGE analysis, the crude membrane fractions were directly
mixed with 4 lithium dodecyl sulfate sample buffer (Invitro-
gen) supplemented with 8% (v/v) -mercaptoethanol and
heated at 95 °C for 5 min. To prepare hippocampal brain
lysates, brains weremicrodissected undermicroscope immedi-
ately after the brains were removed. Hippocampi were then
directly lysed in SDS extraction buffer (10 mM Tris-HCl (pH
6.8), 1.5% SDS, 1 mM EDTA, 150mMNaCl, a protease inhibitor
mixture (RocheApplied Science), 2mMPNT, 2MMG132, and
1mMPMSF). RNeasymini kit (Qiagen)was used to extract total
RNA from the brains. Approximately 30 mg of brain powder
was dissolved in 600l of buffer RLT containing 1% -mercap-
toethanol by vortexing. Lysates were applied to QIAshredder
(Qiagen). The instructions for RNeasy mini kit (Qiagen) were
followed.
Confocal Immunofluorescence Staining of Hippocampal
Sections—BACE1-null, BACE1 heterozygote knock-out, and
wild-type control mice were perfused with 12ml of PBS and 1%
paraformaldehyde, 1% sucrose solution, respectively. Brains
were rapidly removed, further fixed in 1% paraformaldehyde,
1% sucrose solution for 3 h at 4 °C, transferred to 30% sucrose
solution, and incubated for 48 h at 4 °C. 40-m sections were
cut, washed three times with PBS, and incubated with blocking
solution containing 0.1% Triton X-100 and 5% purified goat
IgG (Jackson ImmunoResearch) for 12 h. The sections were
then incubatedwith primary antibody solution containing anti-
Nav1.1 antibody (monoclonal, 1:20 dilution, University of Cal-
ifornia, Davis/National Institutes of Health NeuroMab Facil-
ity), 0.1% Triton X-100, and 5% goat IgG for 24 h 4 °C. After
washing three times, sections were incubated with secondary
antibody solutionwith anti-mouse Alexa Fluor488 (Invitrogen)
for 3 h at room temperature. Immunostained sections were
mounted and analyzed by Olympus IX70 fluorescence micro-
scope equipped with a confocal Disk Spinning Unit (Olympus).
Images were captured and analyzed by IPlab software.
Western Blot Analysis—20–100 g of protein were resolved
on 4–12% gradient BisTris gels, 12% BisTris gels, or 16% Tri-
cine gels (Invitrogen), depending on the individual experiment
as described. The blots were visualized by enhanced chemilu-
minescence (ECL). The images were captured by using BioMax
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film (Eastman Kodak Co.) or VersaDoc imaging system (Bio-
Rad) and quantitated by using QuantityOne software
(Bio-Rad).
Quantitative RT-PCR—Levels of sodium channel genes were
analyzed by quantitative RT-PCR performed in a Light Cycler
PCR system (Bio-Rad). 1 g of total RNA was used for the
synthesis of cDNA using oligo(dT) primers following the pro-
tocol of the SuperScript first-strand synthesis system for RT-
PCR (Invitrogen). Relative quantification of mRNA expression
of Scn1a (Nav1.1) compared with endogenous expression of
GAPDHwas analyzed by TaqMan real time PCR. Primers were
purchased from Applied Biosystems (catalogue numbers
Mn01329052-m1, Mn00488110-m1, and Mn01270368-m1).
Expression analysis was performed with 40 two-step cycles for
30 s at 95 °C and 60 s 60 °C as described in the supplier’s proto-
col (Applied Biosystems) using a Bio-Rad iCycler. Sodium
channelmRNAwas normalized toGAPDHmRNAby the com-
parative CTmethod.
Acute Hippocampal Slice Preparation—Hippocampal neu-
rons from BACE1-transgenic and control mice (1–2 month)
were acutely isolated using standard procedures (26, 33). Mice
were decapitated under deep isoflurane anesthesia, and
brains were rapidly removed and iced. Slices (400m)were cut
and transferred to a low calcium buffer containing 15 mM
HEPES (pH 7.4), 140 mM sodium isethionate, 2 mM KCl, 2 mM
MgCl2, 0.1mMCaCl2, and 23mMglucose. Sliceswere incubated
for more than 1 h in NaHCO3-buffered Earle’s balanced salt
solution (Sigma) bubbled with 95% O2 and 5% CO2 at room
temperature.
Surface Biotinylation—Surface biotinylation of acutely pre-
pared hippocampal slices was performed according to a
method described by Thomas-Crusells et al. (34) with slight
modifications. The slices were prepared as described earlier
and incubated with 100 M Sulfo-NHS-Biotin (Pierce) in Ear-
le’s balanced salt solution bubbled with 95% O2 and 5% on ice
for 80 min under dark conditions. The reaction was stopped by
washing three times with cold Earle’s balanced salt solution
containing 100 M L-lysine. Hippocampal regions were rapidly
separated from the individual slices under a dissecting micro-
scope. The isolated hippocampi were extracted with a lysis
buffer containing 10 mM Tris-HCl (pH 6.8), 1 mM EDTA, 150
mM NaCl, 0.2% SDS, 0.5% sodium deoxycholate, 1% Triton
X-100, and protease inhibitors, followed by a spin at 16,000 g.
Biotinylated proteins were captured by Neutravidin beads
(Pierce) at 4 °C overnight.
Statistical Analyses—All statistical analyses were performed
using a two-tailed Student’s t test or one-wayANOVA followed
by a post hoc Tukey’s test. Error bars represented in graphs
denote the means S.E.
RESULTS
Nav2 Mediates the Effect of BACE1 on Nav1.1 Levels in Pri-
mary Neurons—Previously, we found that BACE1 and -secre-
tase sequentially cleave Nav2 to release the intracellular
domain of Nav2 (2-ICD). In neuroblastoma cells, 2-ICD is
localized to the nucleus and regulatesmRNA and protein levels
of Nav1.1 (32). To test whether endogenous BACE1 activity
regulates Nav1.1 through the processing of Nav2 in vivo, we
treated cultured rat cortical/hippocampal neuronswith BACE1
inhibitors and analyzedNav1.1 levels.We found that DR9 treat-
ment decreased Nav1.1 levels up to 50% in a dose-dependent
manner (Fig. 1A). Interestingly, we also found thatNav1.2 levels
were dose-dependently increased upon DR9 treatment, sug-
gesting potential compensatory changes (supplemental Fig. 1,
A and B). Previously, we have shown that recombinant 2-ICD
expression significantly elevates Scn1a (Nav1.1)mRNA levels in
rat neuroblastoma cells (32). Similarly to Nav1.1, Nav1.2 may
also be regulated at the level of 2-ICD. Therefore, we tested
the effect of recombinant 2-ICD on Scn2a (Nav1.2) mRNA
levels. Unlike Scn1a (Nav1.1), Scn2a (Nav1.2) mRNA levels did
not change in a statistically meaningful way under the same
conditions (supplemental Fig. 1C). These results suggest that a
potential compensatory change of Nav1.2 may not be directly
regulated by 2-ICD.
To explorewhetherNav2 is required for BACE1 activity-de-
pendent Nav1.1 decrease, we took advantage of primary neuro-
nal cultures fromNav2-nullmice (26). Cultured hippocampal/
cortical neurons (14 days in vitro) from wild-type and Nav2-
null mice were treated with BACE1 inhibitors, followed by
analysis of Nav1.1 mRNA and protein levels. As expected, in
wild-type neurons we found that two different BACE inhibi-
tors, DR9 or inhibitor IV, decrease Nav1.1 protein levels by
42–70% (Fig. 1,B andC). Scn1a (Nav1.1)mRNA levels were also
decreased by DR9 or inhibitor IV (supplemental Fig. 1D). These
data show that BACE1 activity is required for maintaining
Nav1.1 levels in cultured rat andmouse neurons. In contrast, in
Nav2-null neurons Nav1.1 levels were unaffected by the same
BACE1 inhibitor treatments (Fig. 1,D and E). These data show
that Nav2 is required for BACE1-dependent regulation of
Nav1.1 levels in cultured embryonic neurons.
Decreased Nav1 Levels in BACE-null Mice—Next, we inves-
tigated whether endogenous BACE1 activity is required for
maintaining normalNav1-subunit levels in adult brains. Brain
samples were prepared from 1- and 3-month-old BACE1-null
(BACE1-KO), BACE1-heterozygous knock-out (BACE1-HE),
and aged-matchedwild-type controlmice (WT). Onemonth of
age was chosen because it is the minimum age for analyzing
adult Nav1s and is also age-compatible with acute preparation
of hippocampal slices without inducing significant neuronal
death. All animals were healthy; however, BACE1-null mice
were generally smaller in size than wild-type and BACE1-HE
animals as reported previously (28). Furthermore, increased
mortality was observed among BACE1-null mice.
We compared total brainNav1-subunits levels in 1-month-
old BACE1-null and BACE1-heterozygous knock-out with age-
matched wild-type mice. To avoid degradation of protease-
prone Nav1 -subunits, brains were rapidly removed,
powdered under liquid nitrogen, aliquoted, and stored at
80 °C until extraction. Because Nav1 -subunits are hydro-
phobic integral membrane proteins, extraction conditions with
strong ionic detergents were required to solubilize -subunits
from insoluble membrane fractions. We compared several
extraction conditions, and we found that extraction with 2%
SDS showed the most consistent results, tightly comparable
with a method based on direct boiling with SDS-PAGE sample
Reduced Nav1.1 Levels in BACE1-null Mice
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loading buffer (Fig. 2; for detailed buffer formulation and con-
ditions, please see “Experimental Procedures”).
Western blot analysis showed more than 50% decrease of
Nav1.1 levels in brain extracts from BACE1-null as compared
with age-matched wild-type control mice, although no signifi-
cant difference was detected between BACE1-heterozygous
knock-out and wild-type controls (Fig. 2). These data suggest
that more than 50% decrease in BACE1 expression is required
for decreasing Nav1.1 levels in adult mouse brains. Interest-
ingly, we also observed significant decreases in Nav1.2 and
Nav1.6 levels, two additional major CNS Nav1 -subunits (Fig.
2). Levels of Nav1.3, an embryonic Nav1 -subunit, did not
change (data not shown). The supplemental Fig. 2 shows a lit-
termate analysis of BACE1-null and BACE1-heterozygous
knock-out mice. As expected, we found more than 50%
decrease of Nav1.1 levels in BACE1-nullmice as comparedwith
BACE1-heterozygous knock-out littermate controls at the
same age.
Finally, we investigated whether the changes in Nav1.1 levels
were also seen in older mice. For this purpose, Nav1 levels were
analyzed in whole brain extracts from 3-month-old BACE1-
null and wild-type control mice (Fig. 3A). Similar to 1-month-
old mice, we observed a significant 20% decrease in Nav1.1
and Nav1.2 levels in BACE1-null mice but no significant
changes in Nav1.6 levels (Fig. 3B). Interestingly, decreases in
Nav1 -subunit levels were less pronounced at 3 months versus
1 month of age, suggesting the possibility that the lack of
BACE1 activity affectsNav1-subunit levelsmore prominently
at early ages (Fig. 3,A andB). High expression of BACE1 in early
postnatal stages may also explain the strong effects of BACE1
knock-out on Nav1 -subunit levels in young mouse brains
(15). Nav1.3 levels were hardly detectable, because this subunit
is predominantly expressed in early developmental stages (data
not shown). Together, these data indicate that endogenous
BACE1 activity regulates Nav1 -subunit levels in adult
neurons.
Nav1.1 Protein Levels in theHippocampus of BACE-nullMice—
We then investigated the effect of BACE1 ablation in the hip-
pocampus, which is a highly affected brain region in patients
with Alzheimer disease. Hippocampal regions were dissected
from the brains of 3-month-oldBACE1-null andwild-type con-
trolmice, extracted, and analyzed forNav1 subunits byWestern
blot analysis. We observed a robust 57% decrease of Nav1.1
levels in BACE1-null as compared with wild-type control mice
(Fig. 4, A and B). Interestingly, we could not detect any signifi-
cant changes in Nav1.2 or Nav1.6 levels in these samples, sug-
gesting that Nav1.1 is the major Nav1 -subunit affected by
BACE1 activity in the hippocampal region (Fig. 4, A and B).
We also investigated Nav1.1 distribution in the hippocampal
region of 3-month-old BACE1-null mice by immunofluores-
cence (Fig. 4C). Using a monoclonal Nav1.1 antibody (Neuro-
mab), wemainly detected Nav1.1 in neuronal cell bodies of hip-
pocampal neurons (35, 36). As shown in Fig. 4C, we found that
Nav1.1 levels were significantly decreased in the dentate gyrus,
hilus, and CA3 regions (Fig. 4C, upper and middle panels). At
higher magnification, we confirmed that somatic Nav1.1 stain-
ing is specifically decreased in BACE1-null mice in the same
regions (Fig. 4C, bottom panels). We also found similar but
FIGURE 1. Nav2 is required for BACE1 activity-dependent regulation of Nav1.1 levels. Primary neuronal culture (14 days in vitro) from Nav2-null mice
(Nav2 KO), wild-type control mice (WT), and wild-type rat were treated with control vehicle (DMSO) or BACE inhibitors (DR9 and/or inhibitor IV) for 48–72 h.
Nav1.1 protein levels were analyzed byWestern blot. A, upper panel, Nav1.1 Western blot analysis of rat primary neurons (14 days in vitro) treated with various
concentrations of DR9 and control vehicle DMSO for 72 h; lower panel, quantitative analysis of Nav1.1 protein levels. B, representative Western blot showing
changes in Nav1.1 levels upon BACE1 inhibitor treatment in cultured WT neurons. C, quantitative analysis of Nav1.1 protein levels upon BACE1 inhibitor
treatment in culturedWTneurons.D, representativeWestern blot showingNav1.1 levels of culturedNav2 KO neurons treatedwithDMSO, DR9, or inhibitor IV.
E, quantitative analysis of Nav1.1 protein levels of cultured Nav2 KO neurons treatedwith DMSO, DR9, or inhibitor IV. One-way ANOVA followed by a post hoc
Tukey’s test was used for statistical analysis (*, p 0.05; n 3 per each condition).
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more dramatic decreases of Nav1.1 in 1-month-old BACE1-
null mice as comparedwith age-matched controls (supplemen-
tal Fig. 3). These data show that ablation of BACE1 significantly
decreases Nav1.1 levels in adult hippocampal neurons.
Altered Surface Nav1 Levels in BACE1-null Brain Slices—In
neurons, newly synthesizedNav1-subunits accumulate inside
the cell body, and only a small fraction of active channels
reaches the cell surface (22). To explore whether endogenous
BACE1 activity modulates surface expression of Nav1 -sub-
units, we performed surface biotinylation analysis using acute
hippocampal slices prepared fromBACE1-HE and BACE1-null
mice as described previously (32). The biotinylated surface pro-
teinswere captured, and total and surfaceNav1-subunit levels
were analyzed by Western blot analysis (Fig. 5A). As expected,
total levels of Nav1.1 were largely decreased in BACE1-null as
compared with BACE1-HE (Fig. 5A, left panel). Similar to the
total Nav1.1 levels, surface levels of Nav1.1 also largely and sig-
nificantly decreased in BACE1-null as compared with
BACE1-HE (Fig. 5A, right panel). When quantitated, we found
32% decrease in BACE1-null as compared with BACE1-HE
control mice (Fig. 5B). Surface expression of Nav1.2 showed a
significant increase, in contrast with Nav1.1 (Fig. 5, A and C).
This suggests a compensatory increase in Nav1.2 sodium
channel density in adult mice. We also compared Nav1.1
surface levels between BACE1-null with wild-type control
mice and found a similar 35% decrease (Fig. 5, D and E). Our
data show that endogenous BACE1 activity regulates surface
expression of Nav1 -subunit levels in adult neurons and
suggest a compensatory regulation between Nav1.1 and
Nav1.2 surface levels.
In addition to Nav1 -subunit surface levels, we also investi-
gated surface expression of full-length Nav2 in acute brain
slices from BACE1-HE and BACE1-null mice. Interestingly, we
found that surface levels of full-lengthNav2 increased by 1.92-
fold in BACE1-null as compared with BACE1-HE (0.06, Fig.
6A). Similarly, the APP, another well known physiological sub-
strate of BACE1, also showed increased surface expression of its
full-length mature form in BACE1-null mice (Fig. 6A). These
surface level changes suggest that ablation of BACE1 decreased
the cleavage of these substrates at the cell surface because
FIGURE2.Nav1-subunit levels aredecreased inbrains fromBACE1-nullmice.Upper left panel,Westernblot showingNav1.1, Nav1.2, andNav1.6-subunit
levels in brainmembrane fractions prepared from1-month-oldwild-type (WT), BACE1-heterozygous knock-out (BACE1-HE), and BACE1-nullmice (BACE1-KO).
Lower left panel, graph showing normalized Nav1.1 protein levels in WT, BACE1-HE, and BACE1-KO normalized against synaptophysin (ANOVA followed by a
post hoc Tukey’s test; *, p 0.05; **, p 0.01;n 3 forWT, BACE1-HE, andBACE1-KO, respectively).Upper right panel, Western blot showingNav1.1, Nav1.2 and
Nav1.6-subunit levels in total brain extract prepared from 1-month-oldWT, BACE1-HE, and BACE1-KO; 2% SDSwas used to extract total brain homogenates.
Lower right panel, a graph showing normalized Nav1.1 protein levels inWT, BACE1-HE, and BACE1-KO normalized against synaptophysin (ANOVA followed by
a post hoc Tukey’s test; **, p 0.01; n 3 for WT, BACE1-HE, and BACE1-KO, respectively).
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BACE1 is known to cleave its substrates at the cell surface or in
the endosomal recycling compartment (37).
Previously, we found that BACE1 and -secretase sequen-
tially cleave Nav2 to release 2-ICD (32). As shown in our
previous study and supplemental Fig. 1C,2-ICD is localized to
the nucleus and regulatesmRNAand protein levels of Nav1.1 in
neuroblastoma cells. To test whether decreased Nav1.1 pro-
teins levels corresponded to reduced Nav2 processing, we
assessed levels of the BACE1 cleavage product Nav2 C-termi-
nal fragment (Nav2-CTF). Consistent with previous reports
(18, 19), we found that ablation of BACE1 reduced generation
ofNav2-CTF by 40% both in total brain extract from 1-month-
old BACE1-KO and in hippocampal regions from 3-month-old
BACE1-KO mice (Fig. 6B). We were not able to directly detect
2-ICD because the Nav2 antibody was not sensitive enough
to detect 2-ICD, which was present in very low levels. How-
ever, together these data strongly suggest that endogenous
BACE1 activity modulates Nav2 processing, and ablation of
BACE1 decreases Nav2-CTF and possibly 2-ICD.
Next, we investigated whether decreased Nav2 processing
also results in reduced Scn1a (Nav1.1) mRNA in brains of
BACE1-null mice (32). In brain samples from 1-month-old
WT, BACE1-HE, and BACE1-null, we measured Scn1a
(Nav1.1) mRNA levels by the TaqMan real time RT-PCR
method. Similar to its protein levels, we found a significant
decrease of Scn1a (Nav1.1) mRNA in BACE1-null as compared
with wild-typemice (Fig. 6C). Interestingly, we were not able to
detect significant changes of Scn2a (Nav1.2) or Scn8a (Nav1.6)
mRNA levels, suggesting that changes at the protein level may
be responsible for decreases in Nav1.2 or Nav1.6 in BACE1-null
mice (supplemental Fig. 4). Together, our mechanistic data
strongly suggest that decreasedNav2 processing is responsible
for the decrease of Nav1.1 protein levels by decreasing scn1a
mRNA in BACE1-null mice.
DISCUSSION
Here, we show that expression levels of three major brain
Nav1 channels are strongly affected by BACE1 deletion during
early postnatal brain development. Levels of the Nav1.1 -sub-
unit showed the most dramatic decrease. These changes are
predicted to have significant effects on the development of
excitability. Ablation of BACE1 results in40–50%decrease of
Nav1.1 protein and mRNA levels in whole brains of 1-month-
old mice and up to 56% in the hippocampus of 3-month-old
mice (Figs. 2–4 and supplemental Figs. 2–4). We also found
that the decrease in Nav1.1 in BACE1-null mice was less pro-
nounced at 3 months versus 1 month of age, suggesting the
possibility that the lack of BACE1 activity affects Nav1 -sub-
unit levels more prominently at early ages. Nav1.2 -subunit
levels were also decreased in whole brain samples from 1- and
3-month-old mice but not in the hippocampus. In addition, we
found that Nav1.6 -subunit levels were also decreased in
brains of 1-month-old but not in 3-month-oldmice. These data
demonstrate that BACE1 regulates adult brain Nav1 -subunit
levels in physiological conditions, possibly in an age-dependent
and/or region-specific manner.
Previously, we reported that BACE1/-secretase activities
promote the release of the 2-ICD, which localizes to the
nucleus and increases mRNA and protein levels of the pore-
forming Nav1.1 -subunit in neuroblastoma cells (18, 32). Ele-
vatedBACE1 activity also increasesNav2 cleavages andNav1.1
levels in brains of BACE1-transgenic mice and AD patients
(32). Although BACE1 cleaves all four -subunits in vitro, only
Nav2 and Nav4 were reported as physiological substrates in
mouse brains (19). Consistent with our previous findings, we
found a significant decrease of Nav2 C-terminal fragment lev-
els in the hippocampus of BACE1-null mice (Fig. 6B). There-
fore, endogenous BACE1 activity is essential forNav2 cleavage
in the hippocampus in vivo. Fig. 1 also suggests a crucial role of
Nav2 in BACE1-dependent regulation of Nav1.1 levels at least
in the embryonic neuronal cells. Although BACE1 inhibitors
largely decreased Scn1a (Nav1.1) mRNA and protein levels in
cultured cortical/hippocampal neurons, the same inhibitors
did not change Nav1.1 levels in Nav2-null neurons (Fig. 1 and
supplemental Fig. 1, A, B, andD). Together, these data support
the notion that Nav2 and its processing are essential for regu-
lating Nav1.1 levels under physiological conditions. Interest-
ingly, we were not able to detect significant changes of Scn2a
(Nav1.2) or Scn8a (Nav1.6) mRNA levels, although Nav1.2 and
Nav1.6 protein levels are significantly decreased in the brains
from 1-month-old BACE1-null mice. This suggests an alterna-
FIGURE 3. Nav1.1 and Nav1.2 are decreased in 3-month-old BACE1-null
mice. A,Western blot showing Nav1.1, Nav1.2, and Nav1.6 -subunit levels in
total brain extracts from 3-month-old wild-type (WT) and BACE1-null mice
(BACE1-KO). B, quantitative analysis showing normalized Nav1.1, Nav1.2, and
Nav1.6 protein levels inWT andBACE1-KO (Student t test; *, p 0.05;n 4 for
both WT and BACE1-KO).
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tive molecular pathway mediating the Nav1.2 or Nav1.6
decrease in BACE1-null mice (Fig. 6C and supplemental Fig. 4).
Altered processing of other neuronal BACE1 substrates may
contribute to these Nav1 -subunit changes. Further studies
will be required to fully characterize the underlying molecular
mechanism of Nav1 -subunit changes.
As shown in Fig. 5, ablation of BACE1 results in 40%
decrease of surface Nav1.1 levels in hippocampal neurons,
which is comparable with the decreased levels of total Nav1.1 in
the same region. Therefore, surface expression of Nav1.1 is reg-
ulated by the decrease of totalNav1.1 levels in BACE1-nullmice
in physiological conditions. On the contrary, we found that
Nav1.2 surface levels are significantly increased (Fig. 5, A and
D). This suggests a compensatory mechanism between Nav1.1
and Nav1.2 surface levels. However, disconnected total versus
cell surface distributions of Nav1.2 in BACE1-null mice are
reminiscent of Nav1.1 distribution in BACE1-overexpressing
systems. In neuroblastoma cells and adult hippocampal neu-
rons from BACE1-transgenic mice, overexpressed BACE1 par-
adoxically reduced cell surface expression of Nav1 -subunits,
although total Nav1.1 -subunits levels increased (32). The
increased Nav1.1 was retained inside the cells and accumulated
in HSP70-positive punctate structures, suggesting that Nav1.1
trafficking to cell surface was inhibited by BACE1 overexpres-
sion (32). Together, these data indicate that expression of Nav1
-subunits on the cell surface is under tight regulation, and
changes in intracellular -subunit levels may not always reflect
surface expression of each channel. Decreased BACE-mediated
cleavage of surface Nav2 may differentially affect Nav1.1 and
Nav1.2 surface trafficking. Further studies will be required to
clarify how BACE1-mediated cleavage of Nav2 can differen-
tially regulate the trafficking of each -subunit.
Neuronal Nav1 channels are known to be up-regulated or
redistributed upon nerve injury or demyelination (38–41). In
experimental allergic encephalomyelitis, an animal model of
multiple sclerosis, levels and distribution of Nav1.2 and Nav1.6
are altered in demyelinated axons within acute multiple sclero-
sis plaques (39–41). BACE1-null mice also show mild but sig-
nificant hypomyelination in the CNS and peripheral nervous
system, and these might contribute to the elevated Nav1.2 sur-
face levels shown inBACE1-nullmice (15, 31, 42). Interestingly,
a recent study showed thatNav2 alsomediates demyelination-
induced Nav1 -subunit regulation in the same multiple scle-
rosismodel (43). Togetherwith our data, this study suggests the
interesting possibility that in BACE1-null mice Nav2 not only
is an essential Nav1 -subunit in regulating changes in Nav1
-subunit levels via generation of its ICD but also indirectly via
reduced myelination, which is a well characterized phenotype
of BACE-null mice. Further studies are required to clarify
whether Nav2 also plays a role in regulating Nav1 -subunit
levels under mild hypomyelination in addition to demyelinat-
ing conditions.
FIGURE4.HippocampalNav1.1 levels aredecreased inBACE1-nullmice.A,Westernblot analysis ofNav1.1, Nav1.2, andNav1.6 fromWTandBACE1-KOmice.
B, quantitative analysis of Nav1.1, Nav1.2, and Nav1.6 levels in hippocampal brain extracts from BACE1-KO andWTmice (Student’s t test; *, p 0.01; n 3 for
WTandn4 for BACE1-KO).C, confocal immunofluorescence analysis ofNav1.1 (green) in hippocampal regionsof 3-month-oldWTorBACE1-KOmice. Top and
middle panels, low magnification (50) images of hippocampal region stained with Nav1.1 staining (green). The red dotted box indicates the area of high
magnification shown in the bottom panels. Bottom panels, high magnification (200) images with Nav1.1 staining (bottom left panel (WT); bottom right panel,
BACE1-KO).
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Deletion of the Nav1.1 gene does not significantly affect
sodium current density in hippocampal pyramidal neurons
because of high expression of Nav1.2 and other -subunits (35,
36, 44). However, Nav1.1 plays a major role in regulating
sodium currents in hippocampal GABAergic interneurons.
Indeed, 50% decrease of Nav1.1 dramatically reduced sodium
current in GABAergic interneurons (36). Similarly, 40–50%
decrease of total and surface Nav1.1 levels in BACE1-null mice
may decrease sodium current in hippocampal GABAergic
interneurons. Thiswould result in electrical imbalances and the
vulnerability to epileptic seizures as previously shown in
Nav1.1-null mice (36). Increase of Nav1.2 surface expression
may also contribute to the electrical imbalances by selectively
increasing sodium currents in hippocampal pyramidal
neurons.
While we were revising this manuscript, two independent
groups reported that BACE1-null mice showed increased sei-
zure susceptibility and spontaneous behavioral seizure pheno-
types (45, 46). These results clearly support our prediction,
based on altered Nav1.1 and Nav1.2 surface expression in
BACE1-null mice (Fig. 5). Hu et al. (45) showed that surface
levels of Nav1.2 are increased in cultured hippocampal neu-
rons from BACE1-null mice, which is also consistent with
our results on increased Nav1.2 surface levels in adult hip-
pocampus from BACE1-null mice (Fig. 5). In addition to
Nav1.2 changes, we also found reduced surface levels of
Nav1.1, which allow us to propose a novel Nav1.1-based
mechanism for the increased seizure susceptibility of
BACE1-null mice (Fig. 6D). Indeed, mutations of the Nav1.1
-subunit are frequently associated with inherited familial
epileptic seizures in humans (44).
Early electrical deficits may also explain the enhanced
lethality of BACE1/2-null mice at very early ages and their
body weight loss (28, 46). Nav1.1-null and -heterozygous
mice show severe and fatal seizure phenotypes (36, 44). A
selective loss of Nav1.1-mediated sodium currents in inhib-
itory neurons is proposed as a molecular mechanism under-
lying these severe phenotypes. Interestingly, all the major
Nav1 -subunit levels are decreased in BACE1-null mice
(Fig. 2) and may not be selective to one neuronal population.
Therefore, neuronal excitability in BACE1-null mice may be
generally reduced all over the brain rather than in specific
circuits, which may not lead to a severe and fatal electrical
imbalance in neural circuits. This may explain why BACE1-
FIGURE 5. Surface Nav1 -subunit levels are altered in BACE1-null hippocampal slices. Surface biotinylation experiments were performed on acutely
prepared hippocampal slices from WT, BACE1-HE, and BACE1-KO mice. 2–3 matching slice pairs from similar locations of the brains were selected for the
experiments. The sliceswith the samenumbers arematchingpairs.A, representativeWesternblot showing total andbiotin-captured surfaceNav1.1 andNav1.2
levels in hippocampal slices (Slice #1–3) fromBACE1-HE and BACE1-KO. B, representativeWestern blot showing total and biotin-captured surface Nav1.1 levels
in hippocampal slices (Slice #1–3) fromwild-type control (WT) and BACE1-KO. C, graph showing quantitated surface Nav1.1 levels in BACE1-HE and BACE1-KO
(Student’s t test; *, p 0.01; n 7 slices from three BACE1-HE and n 8 from three BACE1-KO mice). Surface N-cadherin levels were used to normalize the
surface Nav1.1 and Nav1.2 levels.D, graph showing quantitated surface Nav1.2 levels in BACE1-HE and BACE1-KO (Student’s t test; *, p 0.01; n 7 slices from
three BACE1-HE and n8 from three BACE1-KOmice). E, graph showing quantitated surface Nav1.1 levels inWT and BACE1-KO (Student t test; *, p 0.01; n
8 slices from three WT and BACE1-KOmice, respectively).
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null mice do not show a fatal seizure phenotype as predicted
by the drastic Nav1 -subunit decreases at the early age
(Fig. 2).
Nav1 -subunits are large hydrophobic membrane proteins
with multiple transmembrane domains (24). It is technically
challenging to analyze total Nav1 -subunits because they are
highly insoluble in mild detergent extraction conditions. To
overcome this technical problem, we used several extraction
conditions and compared the results (Fig. 2). We found that
1.5–2% of SDS extraction conditions showed the most consis-
tent results, tightly comparable with a method based on direct
boiling of membrane fractions in the presence of SDS-PAGE
sample loading buffer. The direct boiling method has been
commonly used for sodium channel analysis by other groups
(27, 36). In these conditions, we found that Nav1.1 andNav1.2
levels are consistently decreased especially in young adult
BACE1-null mice as compared with BACE-HE and wild-type
controls (Fig. 2). These data are consistent with the results
fromHu et al. andHitt et al. (45, 46). However, Hitt et al. (46)
reported that Nav1.2 and Nav1.6 levels were not significantly
changed in BACE1-null mice (45). The discrepancy regard-
ing Nav1.2 may derive from differential extraction condi-
tions (2% SDS versus 1% Triton X-100) or different ages of
the mice. Indeed, we found that the decrease in Nav1.2 is
much less pronounced (20%) in 3-month-old mice as com-
pared with 1-month-old mice (40–50%) (Figs. 2 and 3).
Consistent with the data from Hitt et al. (46), we found that
Nav1.2 levels were not significantly changed in the hip-
pocampal region of 3-month-old mice, although Nav1.1
shows a dramatic decrease in the same samples (Fig. 4).
However, Hitt et al. (46) did not analyze levels of Nav1.2 at
the cell surface. Because the vast majority of sodium chan-
nels is retained inside the cells, total Nav1.2 levels may not
reflect changes at the cell surface. We found that Nav1.1
levels decrease at the cell surface, although Nav1.2 levels
increase in agreement with Hu et al. (45). Taken together,
these data argue that the lack of BACE1 activity dynamically
modulates changes in Nav1 -subunit levels depending on
FIGURE 6. Nav2 processing and scn1a (Nav1. 1) mRNA levels are decreased in brains of BACE1-null mice. A, surface Nav2 and APP levels are largely
decreased in brain slices from BACE1-null (BACE1-KO) as compared with BACE1-heterozygous knock-out (BACE1-HE). Slice biotinylation experiments were
performed as described in Fig. 5. B, upper panel, representative Western blot showing full-length Nav2 and C-terminal fragment (Nav2-CTF) levels in
hippocampal brain extracts prepared fromWT and BACE1-KOmice. Lower panel, quantitative analysis of Nav2-CTF levels in total brain extract from 1-month-
oldWTandBACE1-KO (left) andhippocampal extracts from3-month-oldWTandBACE1-KOWTandBACE1-KOmice (right, Student’s t test; *,p 0.01;n 3per
each condition). C, TaqMan real time RT-PCR analysis of scn1a (Nav1.1) mRNA levels in 1-month-oldWT, BACE1-HE, and BACE1-KO (ANOVA followed by a post
hoc Tukey’s test; *, p 0.05; n 5 for WT, n8 for BACE1-HE, and n6 for BACE1 KO). GAPDH levels were used to normalize Scn1a (Nav1.1) mRNA levels.
D, diagram summarizing altered sodium channel metabolism in BACE1-null mice.
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age/brain region and that changes in cell surface Nav1 -sub-
unit levels are likely to cause epileptic seizures in BACE1-
null mice. Further studies will be required to fully address
BACE1 effects on Nav1 -subunit levels in vivo.
BACE1 is one of the prime drug targets for therapeutic
treatment of AD patents. Genetic ablation of BACE1 showed
decreased A levels and ameliorated cognitive function in
animal models (47). Our findings that the ablation of BACE1
leads to decreased sodium channel levels suggest that com-
plete block of BACE1 is likely to cause side effects through
altered sodium current densities. However, our studies on
Nav1 levels in BACE1-heterozygous mice show that 50%
decrease of BACE1 activity does not significantly decrease
Nav1.1 levels (Fig. 1), although partial reduction of BACE1
results in dramatic reduction in A plaques, neuritic burden,
and synaptic deficits in older mice (48). Therefore, it will be
important to find a therapeutic window for inhibiting
BACE1 activity to block A burden, without significantly
affecting Nav1 metabolism.
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